pyrazines has been researched along with Acid Alpha-Glucosidase Deficiency in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eto, Y; Higuchi, T; Ida, H; Kobayashi, H; Nishida, H; Nishiyama, Y; Ohashi, T; Shimada, Y | 1 |
| Bailey, C; Banugaria, SG; Conway, RL; Feldman, JD; Gera, R; Kishnani, PS; Kobori, JA; McGann, JK; Prater, SN; Rosenberg, AS; Tannenbaum, JA; Viskochil, D | 1 |
3 other study(ies) available for pyrazines and Acid Alpha-Glucosidase Deficiency
| Article | Year |
|---|---|
Proteasome inhibitors improve the function of mutant lysosomal α-glucosidase in fibroblasts from Pompe disease patient carrying c.546G>T mutation.
Topics: alpha-Glucosidases; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Enzyme Stability; Fibroblasts; Glycogen Storage Disease Type II; Humans; Leupeptins; Mutation; Proteasome Inhibitors; Protein Transport; Pyrazines | 2011 |
Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease.
Topics: Antibodies; Antineoplastic Agents; Boronic Acids; Bortezomib; Child; Child, Preschool; Drug Therapy, Combination; Glycogen Storage Disease Type II; Humans; Immunoglobulins, Intravenous; Male; Methotrexate; Plasma Cells; Pyrazines; Treatment Outcome | 2013 |
News & views in ... Immunotherapy.
Topics: Allergens; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cattle; Female; Glycogen Storage Disease Type II; Human papillomavirus 16; Human papillomavirus 18; Humans; Hypersensitivity; Immunotherapy; Leukotriene B4; Melanoma; Milk; Milk Proteins; Papillomavirus Infections; Pyrazines; Receptors, Leukotriene B4; Skin Neoplasms; Tumor Escape; Uterine Cervical Neoplasms; Viral Vaccines | 2012 |